{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-117515","form_type":"8-K","ticker":"HIND","cik":"0001427570","company_name":"Vyome Holdings, Inc","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.618183+00:00","generated_at":"2026-06-21T19:49:17.420708+00:00","sec_items":["1.01","3.02","3.03","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ReShape Lifesciences announces $750k offering with Series D preferred and warrant repricing","bullets":["Gross proceeds $750k from sale of 2.39M shares, 2,500 Series D preferred, and pre-funded warrants at $0.26/share.","Common warrants to purchase 2.88M shares at $0.30, exercisable after 6 months, expire 5.5 years.","Existing warrants for 5.35M shares amended: exercise price cut to $0.30, non-exercisable for 6 months, extended expiry.","Company to seek shareholder approval for reverse split and increase authorized shares from 100M to 300M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-117515","json":"https://secwatch.observer/filing/0001104659-22-117515.json","markdown":"https://secwatch.observer/filing/0001104659-22-117515.md","text":"https://secwatch.observer/filing/0001104659-22-117515.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427570/000110465922117515/0001104659-22-117515-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427570/000110465922117515/tm2230281d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T19:49:17.420708+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"61a391ec59774baf7d72a65e38bbc618a4b9d600","claim":"Vyome Holdings, Inc entered into Securities Purchase Agreement valued at $750,000 (effective 2022-11-08).","evidence_excerpt":"On November 8, 2022, ReShape Lifesciences Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a certain institutional investor (the “Investor”), pursuant to which the Company agreed to issue and sell to the Investor in a registered direct offering (the “Registered Offering”) (i) 2,392,524 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), (ii) 2,500 shares of the Company’s Series D Mirroring Preferred Stock, par value $0.001 per share and stated value of $0.001 per share (the “Preferred Stock”), and (iii) pre-funded warrants to purchase an aggregate of 492,091 shares of Common Stock (the “Pre-funded Warrants”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1427570/000110465922117515/0001104659-22-117515-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Value","value":"$750,000"},{"label":"Effective","value":"2022-11-08"}],"fact_type":"material_agreement"},{"claim_id":"c6ce1cf59a24186c120a17c907b8350f9f10d23b","claim":"Vyome Holdings, Inc amended Warrant Amendment Agreement.","evidence_excerpt":"In connection with the Offering, the Company also entered into a warrant amendment agreement (the “Warrant Amendment Agreement”) with the Investor.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1427570/000110465922117515/0001104659-22-117515-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}